Context Therapeutics reports Q3 2026 financials, delivers CTIM-76 RECIST data
Context Therapeutics reported $34.4 million in cash as of Sept. 30, 2026, and announced CTIM-76's weekly dosing produced a 22% confirmed ORR in heavily pretreated ovarian cancer patients. The company is advancing to 420 mcg every three weeks and initiating Phase 1b in Q1 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed